December 9, 2021 12:11 PM EST

Merck enlists Thermo Fisher to make Covid-19 antiviral molnupiravir for Canada, UK

Josh Sullivan

Just after Merck announced a deal to partner with a manufacturer to make its experimental Covid-19 pill molnupiravir in the US, the drugmaker has reached …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck enlists Thermo Fisher to make Covid-19 antiviral molnupiravir for Canada, UK

Josh Sullivan

Sign up to read this article for free.

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Mer­ck en­lists Ther­mo Fish­er to make Covid-19 an­tivi­ral mol­nupi­ravir for Cana­da, UK

Josh Sullivan

Sign up to read this article for free.

more like this

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Pfiz­er, GSK add risk of Guil­lain-Bar­ré to RSV vac­cine la­bels at FDA's re­quest

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

Merck enlists Thermo Fisher to make Covid-19 antiviral molnupiravir for Canada, UK

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic